Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2019 Aug 27;10:916. doi: 10.3389/fphar.2019.00916

ITPA, TPMT, and NUDT15 Genetic Polymorphisms Predict 6-Mercaptopurine Toxicity in Middle Eastern Children With Acute Lymphoblastic Leukemia

Borhan Moradveisi 1, Samar Muwakkit 2, Fatemeh Zamani 3, Ebrahim Ghaderi 4, Ebrahim Mohammadi 5,*, Nathalie K Zgheib 6,*
PMCID: PMC6718715  PMID: 31507415

Abstract

Background: Acute lymphoblastic leukemia (ALL) is the most common cancer seen in children worldwide and in the Middle East. Although there have been major advances in treatment approaches for childhood ALL, serious toxicities do occur but with significant inter-individual variability. The aim of this study is to measure the frequency of polymorphisms in candidate genes involved in 6-Mercaptopurine (6-MP) disposition in a combined cohort of Middle Eastern Children with ALL, and evaluate whether these polymorphisms predict 6-MP intolerance and toxicity during ALL maintenance therapy.

Methods: The study includes children treated for ALL on two treatment protocols from two cohorts; one from Lebanon (N = 136) and another from Kurdistan province of Iran (N = 74). Genotyping for the following six candidate genetic polymorphisms: ITPA 94C > A (rs1127354) and IVS2+21A > C (rs7270101), TPMT*2 238G > C (rs1800462), TPMT*3B 460G > A (rs1800460) and *3C 719A > G (rs1142345), and NUDT15 415C > T (rs116855232) was performed and analyzed in association with 6-MP dose intensity and toxicity.

Results: As expected, TPMT and NUDT15 variants were uncommon. As for ITPA, both polymorphisms were more common in the Lebanese as compared to the Kurdish cohort with a minor allele frequency of 0.05 for 94C > A and 0.14 for IVS2+21A > C in the Lebanese only (N = 121), and of 0.01 for either ITPA polymorphism in Kurds. The most significant toxic effects were depicted with the NUDT15 polymorphism with a median 6-MP dose intensity of 33.33%, followed by 46.65% for TPMT*3A polymorphism, followed by 65.33% for two ITPA risk allele carriers and 74% for one ITPA risk allele carriers, in comparison to a median of 100% for the homozygous wild type in the combined cohort (P < 0.001). In addition, the onset of febrile neutropenia was significantly higher in variant allele carriers in the combined cohorts.

Conclusions: These data confirm the predictive role of TPMT, NUDT15, and ITPA in 6-MP intolerance in Middle Eastern children with ALL. Given the relatively high frequency of ITPA variants in our study and their significant association with 6-MP dose intensity, we recommend that physicians consider genotyping for ITPA variants in conjunction with TPMT and NUDT15 prior to 6-MP therapy in these children.

Keywords: acute lymphoblastic leukemia, pharmacogenetics, ITPA, TPMT, NUDT15

Introduction

Acute lymphoblastic leukemia (ALL) is the most common cancer seen in children worldwide and in the Middle East (Dabbous et al., 2003; An et al., 2017). Although there have been major advances in treatment approaches for childhood ALL, serious toxicities such as profound leukopenia frequently affect treatment and lead to life threatening consequences such as severe infections and even death (Muwakkit et al., 2012; An et al., 2017).

There are currently a number of treatment protocols for childhood ALL, almost all of which entail combination chemotherapy administered in three phases: induction, consolidation with or without re-induction and maintenance (Kato and Manabe, 2018). 6-Mercaptopurine (6-MP) is concomitantly given with Methotrexate (MTX) during consolidation and maintenance. It is a purine antimetabolite, and it is frequently associated with life threatening myelosupression, though with major individual variability (Al-Mahayri et al., 2017; Maxwell and Cole, 2017; Rudin et al., 2017; Koutsilieri et al., 2019).

Driven by this inter-individual variability, a number of investigators have extensively evaluated germline pharmacogenetic (PGx) markers with a focus on candidate pharmacokinetic and pharmacodynamic targets to predict 6-MP toxicity (Al-Mahayri et al., 2017; Maxwell and Cole, 2017; Rudin et al., 2017; Koutsilieri et al., 2019). The oldest and most robust evidence is currently for genetic variants in thiopurine-S-methyltransferase (TPMT), an enzyme that inactivates the drug. For instance, testing for specific decreased enzyme function polymorphisms prior to therapy, mainly TPMT*2, *3A, *3B, and *3C has been included in several clinical guidelines and drug labels (PharmGKB, 2016; PharmGKB, 2018a). More recently, a low function variant in nucleoside diphosphate-linked moiety X motif (NUDT15) was also shown to be associated with decreased thiopurine metabolism (Yang et al., 2015) and, similarly to TPMT polymorphisms, it was clinically annotated as a level 1A variant by the pharmgkb (PharmGKB, 2018b).

These alleles are, however, limited by being relatively uncommon and sometimes confined to specific populations or ethnicities. For example, the NUDT15 variant is rare in Europeans and most common in Asians and Hispanics (Moriyama et al., 2017; Zhou et al., 2018). In addition in the Middle East, we have shown that, although these TPMT and NUDT15 variants are associated with significant 6-MP intolerance, they are also quite uncommon (Zgheib et al., 2017). Therefore, the contribution and ethnic variability of polymorphisms in other genes remains an important and active field of research.

An enzyme that is gaining momentum in the PGx of 6-MP is the inosine triphosphate (ITPA) (Simone et al., 2013). Several studies examined the role of essentially two variants in the ITPA gene (94C > A and IVS2+21A A > C) with 6-MP metabolism (Stocco et al., 2009), as well as toxicity in patients with inflammatory bowel disease (Zelinkova et al., 2006; Ansari et al., 2008; Ban et al., 2010) and children with leukemias of various ethnicities (Adam de et al., 2011; Chiengthong et al., 2016; Milosevic et al., 2018; Zhou et al., 2018; Khera et al., 2019), with promising results. To our knowledge, no data are yet available on the prevalence and role of ITPA genetic polymorphisms with 6-MP toxicity in Middle Eastern populations except for one from Turkey, though with a very small sample size and negative results (Eldem et al., 2018). In addition, although there are few reports on the frequency of TPMT polymorphisms and their association with 6-MP from this area of the world (Hakooz et al., 2010; Albayrak et al., 2011; Bahrehmand et al., 2017), NUDT15 was only recently evaluated in our Lebanese cohort (Zgheib et al., 2017).

The aim of this study is to measure the frequency of polymorphisms in candidate genes involved in 6-MP disposition in a combined cohort of Middle Eastern Children with ALL, and evaluate whether these polymorphisms predict 6-MP intolerance and toxicity during ALL maintenance therapy.

Methods

This study includes children treated for ALL on two treatment protocols from two cohorts; one from Lebanon and another from Kurdistan. Access to clinical data and collection of peripheral blood for DNA isolation was approved by the respective Institutional Review Boards (IRBs), and all subjects and parents signed an informed consent or assent, as applicable.

Patients and Data Collection

Lebanon

This study builds on a previously described cohort of children treated at the Children’s Cancer Center of Lebanon for ALL. Subjects were recruited between 2010 and 2013 (Zgheib et al., 2014; Zgheib et al., 2017; Zgheib et al., 2018), the majority of whom received and finished treatment as per the St Jude Children’s Research Hospital (SJCRH) protocol TOTAL XV (Muwakkit et al., 2012). This protocol consists of an induction followed by consolidation therapy, then a maintenance phase that lasts up to 120 weeks for girls and 143 weeks for boys. The first 20 weeks of maintenance include 2 re-inductions between weeks 7 and 9 and between weeks 17 and 20. During weeks 20 till 100 of maintenance, low risk patients receive 6-MP and MTX with pulses of Dexamethasone, Vincristine, and MTX every 4 weeks. Patients with intermediate and high risk disease receive three rotating drug pairs as such: 2 weeks of 6-MP and MTX, 1 week of Dexamethasone plus Vincristine, and 1 week of Cyclophosphamide and Cytarabine every 28 days. After week 100, only weekly MTX and daily 6-MP are given with dosages being adjusted according to tolerance.

Retrospective chart review was performed for baseline characteristics and treatment information. Specifically for this study, the 6-MP dose intensity (%) was computed as the ratio of the final 6-MP dose to that of the prescribed 6-MP maintenance dose as per protocol (75 mg/m2/day). The 6-MP dose are adjusted so as to maintain the white blood cell count between 1,500 and 3,000 per µl, the absolute neutrophil count (ANC) more than 300 per µl and the platelet count more than 50,000 per µl. Data were also collected on whether patients were admitted for febrile neutropenia during maintenance. In addition, the highest direct bilirubin values reached after week 100 of the maintenance phase were recorded, with hepatotoxicity defined as a value of more or equal to 1.5 mg/dl, a value that is clinically relevant.

Data on the role of TPMT and NUDT15 genetic polymorphisms with 6-MP dose intensity during maintenance therapy were previously published (Zgheib et al., 2017), and this study adds data on the contribution of two polymorphisms in the ITPA gene.

Kurdistan

Seventy-four children with ALL were recruited between 2012 and 2018 at the Besat Hospital, Kurdistan University of Medical Sciences and Health Services, Sanandaj, Kurdistan. All recruited patients were uniformly treated according to the COG protocol (Carroll and Bhatla, 2016) and completed treatment. Similarly to the SJCRH protocol, treatment with the COG protocol starts with an induction phase followed by consolidation and maintenance. During maintenance, patients receive the same starting dose of weekly MTX (20 mg/m2) and daily 6-MP (75 mg/m2) until the end of therapy, accompanied by Vincristine and Prednisone or Dexamethasone pulses every 28 days until the end of maintenance phase. The dose of 6-MP and MTX are adjusted in order to obtain WBC between 2,000–3,000/μl and the ANC more than 500/μl. As such, the doses of 6-MP and MTX are reduced by 25% each time the WBC count is less than 2,000/μl in each visit during therapy.

Retrospective chart review was performed for baseline characteristics and treatment information. Specifically for this study, the 6-MP dose intensity (%) was computed as the ratio of the final 6-MP dose reached during maintenance therapy to maintain the WBC between 2,000 and 3,000 per µl and the ANC more than 500 per µl to that of the prescribed 6-MP maintenance dose as per protocol (75 mg/m2/day). Data were also collected on whether patients were admitted for febrile neutropenia during maintenance. In addition, the highest SGPT/ALT values reached during the maintenance phase were recorded, with hepatotoxicity defined as values at least three times higher than the upper normal limit.

Genotyping

This study entails genotyping for the following six candidate genetic polymorphisms: ITPA 94C > A (rs1127354) and IVS2+21A > C (rs7270101), TPMT*2 238G > C (rs1800462), TPMT*3B 460G > A (rs1800460) and *3C 719A > G (rs1142345) with TPMT*3A being the combination of the TPMT*3B and TPMT*3C genotypes, and NUDT15 415C > T (rs116855232).

Lebanon

Genomic DNA was isolated from 150 μl peripheral blood using the QIAmp Blood MINI kit from Qiagen (Germantown, MD, USA) and stored at -20°C until analysis. Genotyping for the three TPMT polymorphisms was performed using light SNP kits on a Lightcycler from Roche (Roche Diagnostics, Switzerland). The NUDT15 polymorphism and the two ITPA variants were measured using TaqMan® allele discrimination kits (Thermofisher, Waltham, MA, USA) on a CFX384 real-time PCR instrument from Biorad (Hercules, CA, USA). Ten percent of the samples were genotyped twice for reproducibility.

Kurdistan

Genomic DNA was isolated from 300 μl peripheral blood using a commercial kit for isolation of DNA (GeneAll, Seoul, South Korea), according to the manufacturer instructions. Allele-specific PCR analysis was used to evaluate the genetic polymorphism in TPMT exon 5 (G238C; TPMT*2 allele) using standard primer pairs published elsewhere (Yates et al., 1997). The exon 7 (G460A; TPMT* 3B allele) and exon 10 (A719G; TPMT* 3C allele) polymorphisms were determined by PCR-RFLP analysis using MwoI (HpyF10VI) and AccI (XmiI) restriction enzymes (Yates et al., 1997). Exon 7 gave a PCR amplicon of 442 bp, which was not digested in the presence of a variant allele, whereas wild-type allele was digested and was seen as 224 and 114 bp fragments. The 337 bp PCR amplicon from wild-type exon 10 remained undigested after enzyme treatment, whereas the variant allele was digested and was seen as 283 and 90 bp fragments. For NUDT15 genotyping, PCR-RFLP was used using and TaaI (HpyCH4III) restriction enzyme and the specific primers according to Fong et al (Fong et al., 2017). NUDT15 wild-type gave a 191 bp PCR product which remained undigested after enzyme treatment, whereas the variant allele was digested to 122 and 69 bp fragments. A mismatch PCR-RFLP method was used for the amplification and detection of ITPA 94C > A and ITPA IVS2+21A > C using PdmI (XmnI) restriction endonuclease and specific primer pairs (Mollaahmadi et al., 18 A.D). The 94A > C variant allele was seen as an undigested amplicon of 256 bp, whereas the wild-type created fragments of 228 and 28 bp after digestion. The 204 bp amplicon of wild-type ITPA IVS2+21A > C allele was not digested, whereas the IV2+21A > C variant was digested to 175 and 29 bp fragments. The PCR conditions for all above described experiments were as follows: an initial denaturation at 95˚C for 5 min followed by 35 cycles of 30 at 95˚C, 25 at specified annealing temperatures (58˚C for amplification of exon 5 and exon 7 of TPMT, 60˚C for amplification of exon 10 of TPMT and of NUDT15, and 50˚C for amplification of ITPA), 30 at 72˚C, and a final extension for 5 min at 72˚C. The PCR amplicons and RFLP products were electropherized and visualized on 3% agarose gel. Twenty percent of the samples including all variant genotypes were analyzed by Sanger sequencing, and results showed complete compatibility with amplification and enzyme digestion methods.

Statistical Analysis

Data were entered and analyzed in SPSS v.24 (IBM, North Castel, NY, USA). They are presented as mean ± SD, median [Min–Max], or numbers (%) as applicable. Genotype frequencies were computed, and the Minor Allele Frequencies (MAFs) of the Lebanese and Kurds were tested for Hardy Weinberg Equilibrium (HWE) using chi-square test. Baseline characteristics, 6-MP related toxicities and genotypes were compared between the two cohorts using Student t-test and two-sided Fisher exact test for continuous and categorical data respectively.

The associations of the different genotypes with 6-MP related febrile neutropenia and hepatotoxicity were evaluated using the two-sided Fisher exact test. The Kruskall Wallis non-parametric test was used for the association with 6-MP dose intensity. Of note that for the ITPA genotypes, the number of risk alleles were entered in the association analysis. These data are visualized using PRISM software (GraphPad6, La Jolla, CA, USA).

A P-value of less than 0.05 was considered statistically significant.

Results

Sample Characteristics

Baseline characteristics are shown in Table 1 . The Lebanon cohort included 136 subjects almost all of whom were Lebanese except for 15: 7 Palestinians, 5 Syrians, and 3 Iraqis. They were of similar age and gender distribution when compared to the 74 Kurds; nevertheless there were significant differences in the immunophenotype distribution and the treatment protocol risk group allocation.

Table 1.

Baseline characteristics, 6-mercaptopurine (6-MP)-related toxicities and genotypes of children with acute lymphoblastic leukemia (ALL) from 2 cohorts (N = 210).

Variables Lebanon1,2 Kurdistan P-value
Number of subjects 136 74
Treatment protocol SJCRH XV COG
Characteristics
Age Years Mean ± SD 6.63 ± 4.93 6.25 ± 3.07 0.495
Sex Male N (%) 77 (56.6) 43 (58.1)
Female N (%) 59 (43.4) 31 (41.9) 0.884
Treatment risk group Low/standard N (%) 69 (51.1) 58 (78.4)
Mid/high N (%) 66 (48.9) 16 (21.6) < 0.001
ALL immunophenotype Pre B N (%) 107 (81.1) 70 (94.5)
T cell N (%) 22 (16.6) 3 (4.1)
Pre-B with AML N (%) 2 (1.5) 1 (1.4)
Early pre B N (%) 1 (0.8) 0 (0) 0.015
6-MP-related toxicities
6-MP dose intensity3 % Mean ± SD 77.39 ± 21.27 95.38 ± 16.03 < 0.001
Febrile neutropenia4 No N (%) 44 (34.9) 58 (78.4)
Yes N (%) 82 (65.1) 16 (21.6) < 0.001
Hepatotoxicity5 No N (%) 111 (90.2) 65 (87.8)
Yes N (%) 12 (9.8) 9 (12.2) 0.638
Genotypes
ITPA 94C > A CC N (%) 126 (92.7) 72 (97.3)
CA N (%) 9 (6.6) 2 (2.7)
AA N (%) 1 (0.7) 0 (0) 0.481
ITPA IVS2+21A > C AA N (%) 103 (75.7) 73 (98.6)
AC N (%) 30 (22.1) 1 (1.4)
CC N (%) 3 (2.2) 0 (0) < 0.001
TPMT*3A 6 *1/*1 N (%) 133 (97.8) 73 (98.6)
*1/*3A N (%) 3 (2.2) 1 (1.4) 1.000
NUDT15 CC N (%) 135 (99.3) 0 (0)
CT N (%) 1 (0.7) 0 (0) 1.000
Open in a new tab

P-values were generated by two-sided Fisher exact test or Student t-test as applicable.

SJCRH, St Jude’s Children Research Hospital; COG, Children’s Oncology Group.

¹Numbers may not add up to 136 due to some unavailable data.

²Lebanese (121), Palestinian (7), Syrian (5), Iraqi (3).

3 Lebanon: ratio of the MP dose reached during maintenance therapy to maintain the WBC between 1,500 and 3,000 per µl and the ANC > 300 per µl to that of the maintenance prescribed MP dose as per protocol. Kurdistan: ratio of the MP dose reached during maintenance therapy to maintain the WBC between 2,000 and 3,000 per µl and the ANC > 500 per µl to that of the maintenance prescribed MP dose as per protocol.

4Lebanon and Kurdistan: At least one episode of febrile neutropenia during maintenance therapy.

5Lebanon: Highest direct serum bilirubin level being ≥1.5 during the MP and Methotrexate combination therapy phase in maintenance (i.e. week 100 and on). Kurdistan: Highest serum SGPT(ALT) level being at least three times higher than the upper level of normal during the MP and Methotrexate combination therapy phase in maintenance.

6TPMT*3A is a combination of the TPMT*3B and TPMT*3C genotypes.

6-Mercaptopurine Related Toxicities

As shown in Table 1 , the 6-MP dose intensity was significantly lower, and there was a significantly higher incidence of febrile neutropenia in the Lebanon cohort when compared to that of Kurdistan. This is to be expected since significantly more of the ALL children from Kurdistan were treated with the low or standard risk protocol. In addition during maintenance with the COG protocol in Kurdistan, MTX is given at a dose of 20 mg/m² weekly in contrast to 40 mg/m² with the SJCRH protocol in Lebanon.

Genetic Polymorphisms

Table 1 also shows the genotype frequencies. As expected, TPMT and NUDT15 variants were uncommon. As for ITPA, both polymorphisms were more common in the Lebanon cohort as compared to Kurdistan with a MAF of 0.05 for 94C > A and 0.14 for IVS2+21A > C in the Lebanese only (N = 121), and of 0.01 for either ITPA polymorphism in Kurds. All frequencies were in HWE (P > 0.05).

Associations Between Genetic Polymorphisms and 6-Mercaptopurine Related Toxicities

As shown in Figure 1 for the combined and the individual Lebanon and Kurdistan cohorts, the evaluated variant alleles were significantly associated with 6-MP intolerance depicted as lower 6-MP dose intensities in carriers of variant alleles when compared to wild type. The most significant effects were depicted with the NUDT15 polymorphism with a median 6-MP dose intensity of 33.33%, followed by 46.65% for TPMT*3A polymorphism, followed by 65.33% for two ITPA risk allele carriers and 74% for one ITPA risk allele carriers, in comparison to a median of 100% for the homozygous wild type in the combined cohort (P < 0.001).

Figure 1.

Figure 1

Open in a new tab

Association1 between ITPA, TPMT, NUDT15 genetic polymorphisms and 6-mercaptopurine (6-MP) dose intensity2 during maintenance therapy in (A) Combined cohorts (N = 210), (B) Lebanon cohort (N = 136), and (C) Kurdistan cohort (N = 74). 1Kruskall Wallis test; Horizontal lines indicate the mean. 2Lebanon: ratio of the MP dose reached during maintenance therapy to maintain the WBC between 1,500 and 3,000 per µl and the ANC > 300 per µl to that of the maintenance prescribed MP dose as per protocol. Kurdistan: ratio of the MP dose reached during maintenance therapy to maintain the WBC between 2,000 and 3,000 per µl and the ANC > 500 per µl to that of the maintenance prescribed MP dose as per protocol.

As shown in Supp. Table 1 , no significant differences in onset of febrile neutropenia emanated for the Lebanon cohort although the three patients with either TPMT*1/*3A or NUDT15 CT genotypes were admitted for febrile neutropenia. Interestingly, onset of febrile neutropenia was significantly associated with risk allele carriers in Kurds as all four children (two CA for ITPA 94C > A, one AC for ITPA IVS2+21A > C, and one TPMT *1/*3A) had this toxicity during maintenance (P = 0.002), an association that was also significant in the combined cohorts (P < 0.001). Notably, no significant associations appeared with hepatotoxicity in neither combined nor the two separate cohorts ( Supp. Table 2 ).

Discussion

In recent decades, there has been a lot of interest in inter-individual differences in drug metabolizing enzymes in order to better adjust drug dosage and therapy. In this regards, TMPT was the first pharmacogene that showed a substantial association with 6-MP maximum tolerated dose and 6-MP related toxicities leading to the implementation of TPMT genotyping before drug administration (Relling et al., 2013). Similarly, NUDT15, an enzyme involved in detoxification of 6-MP metabolites, showed a strong association with 6-MP intolerance in the maintenance phase of ALL therapy (Moriyama et al., 2016), and it has hence been recently integrated in the updated CPIC guidelines for thiopurine dosing (Relling et al., 2019). However, the frequency of these genetic polymorphisms is noticeably lower in some ethnic groups when compared to others (Hakooz et al., 2010; Albayrak et al., 2011; Bahrehmand et al., 2017; Moriyama et al., 2017; Zgheib et al., 2017; Zhou et al., 2018), hence the need to elicit the role of other variants in other genes that are more relevant to specific populations. This study reports on the frequency and role of TPMT, NUDT15, and ITPA polymorphisms with 6-MP dose intensity and toxicity in two cohorts from the Middle East, one from Lebanon and another from Kurdistan. We have shown that, while variants in the three genes are significant predictors of 6-MP intolerance, TPMT and NUDT15 polymorphisms are quite infrequent, hence the importance of integrating ITPA genotyping in ALL PGx guidelines for this area of the world.

In term of allele frequency ( Table 1 ), results showed 1.4% and 2.2% frequency for the TPMT*3A risk allele in the Lebanese and Kurdish population, respectively. This range is similar to that reported in other studies in West Asian populations (Collie-Duguid et al., 1999), and is far less than the mean global prevalence of TPMT genetic variations which is around 10% (Relling et al., 2013). Besides in our study, only one patient was a carrier for the risk allele of NUDT15 gene, accounting for only 0.4% in the full cohort, a frequency that is very low when compared to Japanese, Taiwanese and Korean people (Tanaka et al., 2015; Liang et al., 2016; Kim et al., 2017). Notably, no patient had a homozygous form of TPMT or NUDT15. More importantly, patients who harbor defective alleles of TMPT and NUDT15 genes required a significantly lower dose of the planned dose of 6-MP compared to the wild-type carriers of these alleles ( Figure 1 ), with 6-MP dose intensity in the one child with the NUDT15 CT genotype being less than that reported in Asian patients with ALL (Yang et al., 2015; Zhou et al., 2018). Therefore, despite the low frequency of TPMT or NUDT15 variant alleles, testing for them prior to therapy is still clinically warranted in this area of the world.

ITPA is another gene candidate involved in 6-MP detoxification with variants reported to be associated with 6-MP intolerance (Hawwa et al., 2008; Wan Rosalina et al., 2012). In this study, and similarly to other numbers reported in the literature (Adam de et al., 2011; Milosevic et al., 2018), the frequency of both evaluated ITPA variants was higher than those in TPMT or NUDT15 for both cohorts, especially for the Lebanon cohort. More importantly, patients with one or two risk alleles of the ITPA gene tolerated a median 74% (33–153%) or 65.33% (53–100%), respectively, of the standard dose of 6-MP. Notably that these dose intensities of 6-MP in ITPA variant groups were higher than those in carriers of the TPMT or NUDT15 variant alleles, but still significantly lower than individuals with no risk alleles (P < 0.001) ( Figure 1 ). In order to evaluate further the relationship between 6-MP toxicity and the tested genotypes, we analyzed the onset of febrile neutropenia and hepatotoxicity among the cohorts in wild-type individuals compared to variant allele carriers. Results showed that none of the variant alleles was associated with hepatotoxicity during maintenance, a negative finding that may be explained by the study design being based on retrospective chart review, or confounded by other concomitant drugs such as MTX (Schmiegelow et al., 2014). Interestingly, the onset of febrile neutropenia was significantly higher in variant allele carriers in Kurds and the combined cohorts, a result that was previously published in other populations (Stocco et al., 2009; Adam de et al., 2011).

In conclusion, these data confirm the predictive role of TPMT, NUDT15, and ITPA in 6-MP intolerance in Middle Eastern children with ALL. Given the relatively high frequency of ITPA variants in our study and their significant association with 6-MP dose intensity, we recommend that physicians consider genotyping for ITPA variants in conjunction with TPMT and NUDT15 prior to 6-MP therapy in these children.

Data Availability

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Ethics Statement

Lebanon: Study is approved by the American University of Beirut Institutional Review Board under protocol: PED.SM.05. All participants and parents signed an informed consent or assent as applicable. Kurdistan: Study is approved by the Kurdistan University of Medical Sciences Institutional Review Board under protocols IR.MUK.REC.1396/102 and IR.MUK.REC.1396/339. All participants and parents signed an informed consent or assent as applicable.

Author Contributions

EM and NZ contributed to the conception and design of the study. BM and SM contributed to the study subjects. FZ and EM carried out the experiments. EM, NZ, and EG organized the database and performed the statistical analysis. EM and NZ wrote the first draft of the manuscript. All authors contributed to manuscript revision and read and approved the submitted version.

Funding

Lebanon: Funding was received from the American University of Beirut Faculty of Medicine Medical Practice Plan. Kurdistan: Funding was received from the research and technology deputy of Kurdistan University of Medical Sciences.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors would like to give special thanks to Professor Jacqueline Cloos from the University of Amsterdam for critically reviewing the Kurdistan cohort data, and Dr. Chi-Chun Ho from Pamela Youde Nethersole Eastern Hospital of Hong Kong for providing control DNA for the NUDT15 polymorphism.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2019.00916/full#supplementary-material

Click here for additional data file. (34.6KB, docx)

References

  1. Adam de B. T., Fakhoury M., Medard Y., Azougagh S., Zhang D., Yakouben K., et al. (2011). Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br. J. Clin. Pharmacol. 71 (4), 575–584. 10.1111/j.1365-2125.2010.03867.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Albayrak M., Konyssova U., Kaya Z., Gursel T., Guntekin S., Percin E. F., et al. (2011). Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia. Cancer Chemother. Pharmacol. 68 (5), 1155–1159. 10.1007/s00280-011-1599-7 [DOI] [PubMed] [Google Scholar]
  3. Al-Mahayri Z. N., Patrinos G. P., Ali B. R. (2017). Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations. Pharmacogenomics 18 (7), 687–699. 10.2217/pgs-2017-0005 [DOI] [PubMed] [Google Scholar]
  4. An Q., Fan C. H., Xu S. M. (2017). Recent perspectives of pediatric leukemia — an update. Eur. Rev. Med. Pharmacol. Sci. 21 (4 Suppl), 31–36. [PubMed] [Google Scholar]
  5. Ansari A., Arenas M., Greenfield S. M., Morris D., Lindsay J., Gilshenan K., et al. (2008). Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 28 (8), 973–983. 10.1111/j.1365-2036.2008.03788.x [DOI] [PubMed] [Google Scholar]
  6. Bahrehmand F., Vaisi-Raygani A., Kiani A., Bashiri H., Zobeiri M., Tanhapour M., et al. (2017). Whole-Blood Thiopurine S-Methyltransferase Genotype and Phenotype Concordance in Iranian Kurdish Ulcerative Colitis (UC) Patients. Clin. Lab. 63 (5), 947–954. 10.7754/Clin.Lab.2017.161201 [DOI] [PubMed] [Google Scholar]
  7. Ban H., Andoh A., Imaeda H., Kobori A., Bamba S., Tsujikawa T., et al. (2010). The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J. Gastroenterol. 45 (10), 1014–1021. 10.1007/s00535-010-0248-y [DOI] [PubMed] [Google Scholar]
  8. Carroll W. L., Bhatla T., (2016). “Acute Lymphoblastic Leukemia,” in Lanzkowsky’s Manual of Pediatric Hematology and Oncology, 6 ed. Eds. Lanzkowsky P., Lipton J. M., Fish J. D. (London: Elsevier; ), 367–389. 10.1016/B978-0-12-801368-7.00018-1 [DOI] [Google Scholar]
  9. Chiengthong K., Ittiwut C., Muensri S., Sophonphan J., Sosothikul D., Seksan P., et al. (2016). NUDT15 c.415C > T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica 101 (1), e24–e26. 10.3324/haematol.2015.134775 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Collie-Duguid E. S., Pritchard S. C., Powrie R. H., Sludden J., Collier D. A., Li T., et al. (1999). The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9 (1), 37–42. 10.1097/00008571-199902000-00006 [DOI] [PubMed] [Google Scholar]
  11. Dabbous I. A., Dbouk H., Sibai A. M., Bahlawan L. (2003). Childhood acute lymphoblastic leukemia managed in tertiary care center in a developing country. Med. Pediatr. Oncol. 41 (1), 83–84. 10.1002/mpo.10139 [DOI] [PubMed] [Google Scholar]
  12. Eldem I., Yavuz D., Cumaogullari O., Ileri T., Inc, Unal, Ertem M., et al. (2018). SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy. J. Pediatr. Hematol. Oncol. 40 (5), e289– e294. 10.1097/MPH.0000000000001153 [DOI] [PubMed] [Google Scholar]
  13. Fong W. Y., Ho C. C., Poon W. T. (2017). Comparison of direct sequencing, real-time PCR-High Resolution Melt (PCR-HRM) and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis for genotyping of common thiopurine intolerant variant alleles NUDT15 c.415C > T and TPMT c.719A > G (TPMT*3C). Diagnostics (Basel) 7 (2), E27. 10.3390/diagnostics7020027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hakooz N., Arafat T., Payne D., Ollier W., Pushpakom S., Andrews J., et al. (2010). Genetic analysis of thiopurine methyltransferase polymorphism in the Jordanian population. Eur. J. Clin. Pharmacol. 66 (10), 999–1003. 10.1007/s00228-010-0826-1 [DOI] [PubMed] [Google Scholar]
  15. Hawwa A. F., Millership J. S., Collier P. S., Vandenbroeck K., McCarthy A., Dempsey S., et al. (2008). Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br. J. Clin. Pharmacol. 66 (4), 517–528. 10.1111/j.1365-2125.2008.03248.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kato M., Manabe A. (2018). Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr. Int. 60 (1), 4–12. 10.1111/ped.13457 [DOI] [PubMed] [Google Scholar]
  17. Khera S., Trehan A., Bhatia P., Singh M., Bansal D., Varma N. (2019). Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother. Pharmacol. 83 (2), 341–348. 10.1007/s00280-018-3732-3 [DOI] [PubMed] [Google Scholar]
  18. Kim H. T., Choi R., Won H. H., Choe Y. H., Kang B., Lee K., et al. (2017). NUDT15 genotype distributions in the Korean population. Pharmacogenet. Genomics 27 (5), 197–200. 10.1097/FPC.0000000000000274 [DOI] [PubMed] [Google Scholar]
  19. Koutsilieri S., Caudle K. E., Alzghari S. K., Monte A. A., Relling M. V., Patrinos G. P. (2019). Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: it takes two to tango. Am. J. Hematol. 94 (7), 737–740. 10.1002/ajh.25485 [DOI] [PubMed] [Google Scholar]
  20. Liang D. C., Yang C. P., Liu H. C., Jaing T. H., Chen S. H., Hung I. J., et al. (2016). NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 16 (6), 536–539. 10.1038/tpj.2015.75 [DOI] [PubMed] [Google Scholar]
  21. Maxwell R. R., Cole P. D. (2017). Pharmacogenetic predictors of treatment-related toxicity among children with acute lymphoblastic leukemia. Curr. Hematol. Malig. Rep. 12 (3), 176–186. 10.1007/s11899-017-0376-z [DOI] [PubMed] [Google Scholar]
  22. Milosevic G., Kotur N., Krstovski N., Lazic J., Zukic B., Stankovic B., et al. (2018). Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia. J. Med. Biochem. 37 (3), 320–327. 10.1515/jomb-2017-0060 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mollaahmadi F., Moini A., Yazdi R. S., Behmanesh M. (2018). The rs1127354 polymorphism in ITPA is associated with susceptibility to infertility. Cell J. 20 (1), 73–77. 10.22074/cellj.2018.4255 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Moriyama T., Nishii R., Perez-Andreu V., Yang W., Klussmann F. A., Zhao X., et al. (2016). NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat. Genet. 48 (4), 367–373. 10.1038/ng.3508 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Moriyama T., Yang Y. L., Nishii R., Ariffin H., Liu C., Lin T. N., et al. (2017). Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood 130 (10), 1209–1212. 10.1182/blood-2017-05-782383 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Muwakkit S., Al-Aridi C., Samra A., Saab R., Mahfouz R. A., Farra C., et al. (2012). Implementation of an intensive risk-stratified treatment protocol for children and adolescents with acute lymphoblastic leukemia in Lebanon. Am. J. Hematol. 87 (7), 678–683. 10.1002/ajh.23222 [DOI] [PubMed] [Google Scholar]
  27. PharmGKB (2016). Annotation of CPIC Guideline for mercaptopurine and TPMT. https://www.pharmgkb.org/guidelineAnnotation/PA166104945.
  28. PharmGKB (2018. a). Mercaptopurine label annotation. https://www.pharmgkb.org/search?gaSearch=mercaptopurine&query=mercaptopurine&resourcesString=&type=LabelAnnotation.
  29. PharmGKB (2018. b). Mercaptopurine clinical annotation. https://www.pharmgkb.org/search?gaSearch=mercaptopurine&query=mercaptopurine&resourcesString=&type=ClinicalAnnotation.
  30. Relling M. V., Gardner E. E., Sandborn W. J., Schmiegelow K., Pui C. H., Yee S. W., et al. (2013). Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther. 93 (4), 324–325. 10.1038/clpt.2013.4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Relling M. V., Schwab M., Whirl-Carrillo M., Suarez-Kurtz G., Pui C. H., Stein C. M., et al. (2019). Clinical Pharmacogenetics Implementation Consortium Guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin. Pharmacol. Ther. 105 (5), 1095–1105. 10.1002/cpt.1304 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Rudin S., Marable M., Huang R. S. (2017). The promise of pharmacogenomics in reducing toxicity during acute lymphoblastic leukemia maintenance treatment. Genomics Proteomics Bioinformatics 15 (2), 82–93. 10.1016/j.gpb.2016.11.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schmiegelow K., Nielsen S. N., Frandsen T. L., Nersting J. (2014). Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J. Pediatr. Hematol. Oncol. 36 (7), 503–517. 10.1097/MPH.0000000000000206 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Simone P. D., Pavlov Y. I., Borgstahl G. E. (2013). ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogenetics. Mutat. Res. 753 (2), 131–146. 10.1016/j.mrrev.2013.08.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Stocco G., Cheok M. H., Crews K. R., Dervieux T., French D., Pei D., et al. (2009). Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85 (2), 164–172. 10.1038/clpt.2008.154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tanaka Y., Kato M., Hasegawa D., Urayama K. Y., Nakadate H., Kondoh K., et al. (2015). Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br. J. Haematol. 171 (1), 109–115. 10.1111/bjh.13518 [DOI] [PubMed] [Google Scholar]
  37. Wan Rosalina W. R., Teh L. K., Mohamad N., Nasir A., Yusoff R., Baba A. A., et al. (2012). Polymorphism of ITPA 94C > A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine. J. Clin. Pharm. Ther. 37 (2), 237–241. 10.1111/j.1365-2710.2011.01272.x [DOI] [PubMed] [Google Scholar]
  38. Yang J. J., Landier W., Yang W., Liu C., Hageman L., Cheng C., et al. (2015). Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J. Clin. Oncol. 33 (11), 1235–1242. 10.1200/JCO.2014.59.4671 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Yates C. R., Krynetski E. Y., Loennechen T., Fessing M. Y., Tai H. L., Pui C. H., et al. (1997). Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126 (8), 608–614. 10.7326/0003-4819-126-8-199704150-00003 [DOI] [PubMed] [Google Scholar]
  40. Zelinkova Z., Derijks L. J., Stokkers P. C., Vogels E. W., van Kampen A. H., Curvers W. L., et al. (2006). Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin. Gastroenterol. Hepatol. 4 (1), 44–49. 10.1016/j.cgh.2005.10.019 [DOI] [PubMed] [Google Scholar]
  41. Zgheib N. K., Akika R., Mahfouz R., Aridi C. A., Ghanem K. M., Saab R., et al. (2017). NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children’s Cancer Center of Lebanon. Pediatr. Blood Cancer 64 (1), 146–150. 10.1002/pbc.26189 [DOI] [PubMed] [Google Scholar]
  42. Zgheib N. K., Akra-Ismail M., Aridi C., Mahfouz R., Abboud M. R., Solh H., et al. (2014). Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet. Genomics 24 (8), 387–396. 10.1097/FPC.0000000000000069 [DOI] [PubMed] [Google Scholar]
  43. Zgheib N. K., Ghanem K. M., Tamim H., Aridi C., Shahine R., Tarek N., et al. (2018). Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet. Genomics 28 (8), 189–195. 10.1097/FPC.0000000000000345 [DOI] [PubMed] [Google Scholar]
  44. Zhou H., Li L., Yang P., Yang L., Zheng J. E., Zhou Y., et al. (2018). Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? BMC Cancer 18 (1), 516. 10.1186/s12885-018-4398-2 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (34.6KB, docx)

Data Availability Statement

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES